No ASX ETF holds Starpharma (SPL) as of 15 Oct 2026. Over the last 3 months it rose 2.7%: on $10,000, +$274. We explain 6 big moves in that time.
About SPL
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$398.2m
- Held by0 ETFs
- Big moves6 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −8.6%peak −10.3%1 Oct 2026· Management
A board chair and deputy chair appointment announcement appears to have unsettled investors, driving an outsized sell-off beyond what sector weakness alone can explain.
- +4.3%peak +5.8%13 Aug 2026· Stake Change
Multiple directors purchased shares through the recently completed $32 million entitlement offer, signalling strong insider confidence and prompting a positive market re-rating of the stock.
- −5.4%12 Aug 2026· Capital Raise
Starpharma launched a $32 million capital raise, causing dilution and a sharp drop in the stock price.
- −7.5%peak −19.9%11 Aug 2026· Capital Raise
Starpharma's stock fell sharply after completing a $32 million renounceable entitlement offer, with new shares being quoted, causing dilution-driven selling pressure.
- +6.7%peak +8.0%5 Aug 2026· Unknown
SPL.AX rose sharply alongside a broader lift in the ASX healthcare sector, likely driven by a general sector rotation or positive sentiment across health stocks rather than any company-specific news.
- +8.0%28 Jul 2026· Sector Flow
SPL.AX rose strongly alongside a broad rally in Australian healthcare sector stocks, lifting the stock on sector-wide buying momentum.
Held by 0 ETFs
No ETF we track holds SPL directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did SPL rise 6.7% on 5 Aug 2026?
Starpharma
SPL.AX rose sharply alongside a broader lift in the ASX healthcare sector, likely driven by a general sector rotation or positive sentiment across health stocks rather than any company-specific news.
The only corroborating signal is a modest 1.19% gain in the ASX Health sector index (^AXHJ), which moved in the same direction but did not itself exceed its normal daily range threshold — suggesting sector tailwind is a partial but not dominant explanation. No company announcements, news articles, or peer-specific signals were found to explain the 6.67% move, which is 3x SPL's normal daily range and therefore outsized relative to the sector move. The elevated volume (1.65x normal) hints at a specific catalyst such as an unannounced deal, speculative buying, or thin liquidity amplifying a small order flow, but without direct evidence this remains inconclusive.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
Sector / macro signals